Home

Idealmente sventura marchio nutlin 3 clinical trial Continente Cosiddetto competenza

Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for  Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53

Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3 | Circulation  Research
Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3 | Circulation Research

Cancers | Free Full-Text | Helping the Released Guardian: Drug Combinations  for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists | HTML
Cancers | Free Full-Text | Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists | HTML

Nutlin-3 | STEMCELL Technologies
Nutlin-3 | STEMCELL Technologies

Adaptation of cancer cells from different entities to the MDM2 inhibitor  nutlin-3 results in the emergence of p53-mutated multi-drug-resistant  cancer cells | Cell Death & Disease
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells | Cell Death & Disease

Nutlin-3 | CAS 548472-68-0 | AbMole BioScience | Nutlin-3 Price
Nutlin-3 | CAS 548472-68-0 | AbMole BioScience | Nutlin-3 Price

The sensitivity to MDM2 antagonists, Nutlin-3 and RG7388, and rucaparib...  | Download Scientific Diagram
The sensitivity to MDM2 antagonists, Nutlin-3 and RG7388, and rucaparib... | Download Scientific Diagram

Targeted nutlin-3a loaded nanoparticles inhibiting p53–MDM2 interaction:  novel strategy for breast cancer therapy | Nanomedicine
Targeted nutlin-3a loaded nanoparticles inhibiting p53–MDM2 interaction: novel strategy for breast cancer therapy | Nanomedicine

The MDM2 ligand Nutlin-3 differentially alters expression of the immune  blockade receptors PD-L1 and CD276 | Cellular & Molecular Biology Letters |  Full Text
The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276 | Cellular & Molecular Biology Letters | Full Text

Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3 | Circulation  Research
Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3 | Circulation Research

The MDM2 ligand Nutlin-3 differentially alters expression of the immune  blockade receptors PD-L1 and CD276 | Cellular & Molecular Biology Letters |  Full Text
The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276 | Cellular & Molecular Biology Letters | Full Text

Oridonin synergizes with Nutlin-3 in inhibition of cell viability of OS...  | Download Scientific Diagram
Oridonin synergizes with Nutlin-3 in inhibition of cell viability of OS... | Download Scientific Diagram

MDM2 antagonists as a novel treatment option for acute myeloid leukemi | OTT
MDM2 antagonists as a novel treatment option for acute myeloid leukemi | OTT

Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1  function in neuroblastoma | British Journal of Cancer
Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma | British Journal of Cancer

p53 programmes plough on
p53 programmes plough on

Nutlin-3 upregulates noxa and induces apoptosis. (a and b)... | Download  Scientific Diagram
Nutlin-3 upregulates noxa and induces apoptosis. (a and b)... | Download Scientific Diagram

Frontiers | Restoring p53 Function in Head and Neck Squamous Cell Carcinoma  to Improve Treatments | Oncology
Frontiers | Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments | Oncology

Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced  cytotoxicity
Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity

Extended treatment with Nutlin-3 results in reduced sensitivity without...  | Download Scientific Diagram
Extended treatment with Nutlin-3 results in reduced sensitivity without... | Download Scientific Diagram

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer:  Implications for therapy | PNAS
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy | PNAS

Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin- 3 in acute myeloid leukemia | Leukemia
Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin- 3 in acute myeloid leukemia | Leukemia

Nutlin - Wikipedia
Nutlin - Wikipedia

The hydrophobically-tagged MDM2–p53 interaction inhibitor Nutlin-3a-HT is  more potent against tumor cells than Nutlin-3a - Chemical Communications  (RSC Publishing) DOI:10.1039/C9CC07795B
The hydrophobically-tagged MDM2–p53 interaction inhibitor Nutlin-3a-HT is more potent against tumor cells than Nutlin-3a - Chemical Communications (RSC Publishing) DOI:10.1039/C9CC07795B

Idasanutlin (RG-7388) | ≥99%(HPLC) | Selleck | Mdm2 inhibitor
Idasanutlin (RG-7388) | ≥99%(HPLC) | Selleck | Mdm2 inhibitor

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer:  Implications for therapy | PNAS
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy | PNAS